![Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation](https://www.ahajournals.org/cms/asset/2514dc29-80c9-4360-9eba-1d2aca429823/54fig01.jpeg)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation
Silvia Cristina Mărginean Claudia Ogrean Ramona Orăștean Editors 2017 International Economics Conference in Sibiu (IECS)
Silvia Cristina Mărginean Claudia Ogrean Ramona Orăștean Editors 2017 International Economics Conference in Sibiu (IECS)
![Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure | Circulation](https://www.ahajournals.org/cms/asset/a1bc1993-9784-42e4-a1be-45c14aa4ce7d/54fig02.jpeg)